Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 33

Results For "Chief-Executive-Officer"

898 News Found

AxoSim appoints Alif Saleh as CEO
People | June 14, 2024

AxoSim appoints Alif Saleh as CEO

Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer


Borosil Scientific debuts on stock exchange
News | June 08, 2024

Borosil Scientific debuts on stock exchange

This strategic decision will unlock significant value for our scientific and industrial products business


Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA
Drug Approval | June 01, 2024

Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes


Merck to acquire EyeBio for US$ 1.3 billion upfront payment
News | May 30, 2024

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration


Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)
News | May 27, 2024

Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)

Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)


Taro shareholders approve merger with Sun Pharma
News | May 24, 2024

Taro shareholders approve merger with Sun Pharma

The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world


AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
News | May 22, 2024

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs


AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
News | May 22, 2024

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030


AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
News | May 14, 2024

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders